We narrowed to 312 results for: cha

#20298-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 8, 2020

Academic Institutions and Nonprofits only

#131000-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-mScarlet (#131000). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-mScarlet plasmid DNA. CamKIIa-driven expression of mScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2023

Academic Institutions and Nonprofits only

#131001-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-mScarlet (#131001). In addition to the viral particles, you will also receive purified pAAV-hSyn-mScarlet plasmid DNA. Synapsin-driven mScarlet control vector. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Nov. 29, 2021

Academic Institutions and Nonprofits only

#131001-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-mScarlet (#131001). In addition to the viral particles, you will also receive purified pAAV-hSyn-mScarlet plasmid DNA. Synapsin-driven mScarlet control vector. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2023

Academic Institutions and Nonprofits only

#131002-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only

#119744-AAV5

Ready-to-use AAV5 particles produced from AAV CAMKII PSAM4 GlyR IRES EGFP (#119744). In addition to the viral particles, you will also receive purified AAV CAMKII PSAM4 GlyR IRES EGFP plasmid DNA. CamKII-driven expression of PSAM4 GlyR IRES EGFP for neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Magnus et al Science. 2019 Mar 14. pii: science.aav52

Aug. 28, 2020

Academic Institutions and Nonprofits only

#128434-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-tdTomato (#128434). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-tdTomato plasmid DNA. EF1a-driven, Flp-dependent expression of tdTomato. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

March 12, 2021

Academic Institutions and Nonprofits only

#128315-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-GCaMP6f (#128315). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-GCaMP6f plasmid DNA. EF1a-driven, Flp-dependent expression of calcium sensor GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

March 12, 2021

Academic Institutions and Nonprofits only

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#119742-AAV5

Ready-to-use AAV5 particles produced from AAV SYN PSAM4 GlyR IRES EGFP (#119742). In addition to the viral particles, you will also receive purified AAV SYN PSAM4 GlyR IRES EGFP plasmid DNA. Synapsin-driven expression of PSAM4 GlyR IRES EGFP for neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Magnus et al Science. 2019 Mar 14. pii: science.aav52

Aug. 28, 2020

Academic Institutions and Nonprofits only

#58880-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. Humanized channelrhodopsin H134R mutant fused to GFP, under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Boyden et al Nat Neurosci. 2005 Sep . 8(9):1263-8.

June 20, 2017

Academic Institutions and Nonprofits only

#131002-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Nov. 29, 2021

Academic Institutions and Nonprofits only

#99039-AAV5

Ready-to-use AAV5 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 21, 2018

Academic Institutions and Nonprofits only

#22222-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#22222-AAV9

Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 20, 2018

Academic Institutions and Nonprofits only

#116869-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-H2B-GFP (#116869). In addition to the viral particles, you will also receive purified pAAV-CAG-H2B-GFP plasmid DNA. CAG-driven expression of H2B-GFP. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Economo et al Nature. 2018 Nov;563(7729):79-84. doi: 1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#116870-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-H2B tdTomato (#116870). In addition to the viral particles, you will also receive purified pAAV-CAG-H2B tdTomato plasmid DNA. CAG-driven expression of H2B-tdTomato. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Economo et al Nature. 2018 Nov;563(7729):79-84. doi: 1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#137135-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-oScarlet (#137135). In addition to the viral particles, you will also receive purified pAAV-Ef1a-oScarlet plasmid DNA. EF1a-driven expression of oScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#106192-AAV1

Ready-to-use AAV1 particles produced from pAAV.GFAP.SF-iGluSnFR.A184S (#106192). In addition to the viral particles, you will also receive purified pAAV.GFAP.SF-iGluSnFR.A184S plasmid DNA. GFAP-driven expression of SF-iGluSnFR.A184S. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Sept. 11, 2020

Academic Institutions and Nonprofits only

#171027-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

July 21, 2023

Academic Institutions and Nonprofits only